Bukwang Pharm Valuation
| 003000 Stock | 4,860 215.00 4.63% |
At this time, the firm appears to be overvalued. Bukwang Pharm shows a prevailing Real Value of USD4062.45 per share. The current price of the firm is USD4860.0. Our model approximates the value of Bukwang Pharm from analyzing the firm fundamentals such as Return On Equity of -0.0168, current valuation of 552.14 B, and Profit Margin of (0.01) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bukwang Pharm's price fluctuation is very steady at this time. Calculation of the real value of Bukwang Pharm is based on 3 months time horizon. Increasing Bukwang Pharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bukwang Pharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bukwang Stock. However, Bukwang Pharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4860.0 | Real 4062.45 | Hype 4860.0 |
The real value of Bukwang Stock, also known as its intrinsic value, is the underlying worth of Bukwang Pharm Company, which is reflected in its stock price. It is based on Bukwang Pharm's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bukwang Pharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bukwang Pharm helps investors to forecast how Bukwang stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bukwang Pharm more accurately as focusing exclusively on Bukwang Pharm's fundamentals will not take into account other important factors: Bukwang Pharm Total Value Analysis
Bukwang Pharm is presently forecasted to have takeover price of 552.14 B with market capitalization of 627.05 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bukwang Pharm fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
552.14 B | 627.05 B |
Bukwang Pharm Investor Information
About 30.0% of the company shares are owned by insiders or employees . The company last dividend was issued on the 29th of December 2021. Bukwang Pharm had 1:1 split on the 29th of December 2020. Based on the analysis of Bukwang Pharm's profitability, liquidity, and operating efficiency, Bukwang Pharm is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Bukwang Pharm Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Bukwang suggests not a very effective usage of assets in November.Bukwang Pharm Ownership Allocation
Bukwang Pharm holds a total of 68.45 Million outstanding shares. Bukwang Pharm retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bukwang Pharm Profitability Analysis
The company reported the revenue of 182.49 B. Net Loss for the year was (916.62 M) with profit before overhead, payroll, taxes, and interest of 75.55 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bukwang Pharm's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bukwang Pharm and how it compares across the competition.
About Bukwang Pharm Valuation
The stock valuation mechanism determines Bukwang Pharm's current worth on a weekly basis. Our valuation model uses a comparative analysis of Bukwang Pharm. We calculate exposure to Bukwang Pharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bukwang Pharm's related companies.8 Steps to conduct Bukwang Pharm's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bukwang Pharm's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bukwang Pharm's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bukwang Pharm's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bukwang Pharm's revenue streams: Identify Bukwang Pharm's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bukwang Pharm's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bukwang Pharm's growth potential: Evaluate Bukwang Pharm's management, business model, and growth potential.
- Determine Bukwang Pharm's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bukwang Pharm's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Bukwang Stock analysis
When running Bukwang Pharm's price analysis, check to measure Bukwang Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bukwang Pharm is operating at the current time. Most of Bukwang Pharm's value examination focuses on studying past and present price action to predict the probability of Bukwang Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bukwang Pharm's price. Additionally, you may evaluate how the addition of Bukwang Pharm to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |